- Home
- ARCT vs HUMA Comparison
ARCT vs HUMA Comparison
Compare ARCT & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- HUMA
- Stock Information
- Founded
- ARCT 2013
- HUMA 2004
- Country
- ARCT United States
- HUMA United States
- Employees
- ARCT N/A
- HUMA N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- HUMA Health Care
- Exchange
- ARCT Nasdaq
- HUMA Nasdaq
- Market Cap
- ARCT 487.0M
- HUMA 584.8M
- IPO Year
- ARCT N/A
- HUMA N/A
- Fundamental
- Price
- ARCT $15.88
- HUMA $4.37
- Analyst Decision
- ARCT Strong Buy
- HUMA Strong Buy
- Analyst Count
- ARCT 8
- HUMA 7
- Target Price
- ARCT $61.00
- HUMA $13.43
- AVG Volume (30 Days)
- ARCT 405.9K
- HUMA 2.4M
- Earning Date
- ARCT 03-06-2025
- HUMA 03-21-2025
- Dividend Yield
- ARCT N/A
- HUMA N/A
- EPS Growth
- ARCT N/A
- HUMA N/A
- EPS
- ARCT N/A
- HUMA N/A
- Revenue
- ARCT $160,399,000.00
- HUMA N/A
- Revenue This Year
- ARCT $7.33
- HUMA N/A
- Revenue Next Year
- ARCT $4.71
- HUMA $4,344.68
- P/E Ratio
- ARCT N/A
- HUMA N/A
- Revenue Growth
- ARCT N/A
- HUMA N/A
- 52 Week Low
- ARCT $14.30
- HUMA $2.81
- 52 Week High
- ARCT $45.00
- HUMA $9.97
- Technical
- Relative Strength Index (RSI)
- ARCT 41.74
- HUMA 45.11
- Support Level
- ARCT $16.03
- HUMA $4.20
- Resistance Level
- ARCT $17.95
- HUMA $4.78
- Average True Range (ATR)
- ARCT 1.29
- HUMA 0.28
- MACD
- ARCT -0.07
- HUMA -0.02
- Stochastic Oscillator
- ARCT 10.29
- HUMA 42.17
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.